2014 ASCO: First results of a Phase 2 study using a 10-day SC regimen of the HMA SGI-110 for r/r AML

/in

Summary

  • Relapsed/refractory AML (r/r AML) is often drug-resistant with high mortality
  • Hypomethylating agents (HMAs) such as decitabine and azacitidine have shown some clinical activity in r/r AML
  • SGI-110 is next generation hypomethylating agent (HMA) given as a small volume subcutaneous (SC) administration
  • We previously presented phase 2 data of SGI-110 in heavily pretreated r/r AML using a standard 5-day regimen Q 28 days showing an overall Complete Remission (CR+CRp+CRi) rate of 16% (Kantarjian et al, ASH, 2013)
  • Here we present the first phase 2 results of SGI-110 given SC in a 10-day regimen Q 28 days

View further details below
2014 ASCO: First results of a Phase 2 study using a 10-day SC regimen of the HMA SGI-110 for r/r AML